CYTOX LIFE SCIENCES

For investing or partnering interest, please click here

Transforming outcomes in acute-on-chronic liver failure

We are developing an extracorporeal liver support system to rescue the sickest patients with acute-on-chronic liver failure (ACLF), those in intensive care with two or more organ failures, ACLF 2-3.
Acute-on-chronic liver failure (ACLF) is a life-threatening complication of advanced liver disease, where patients suddenly experience acute hepatic decompensation with one or more organ failures.
High mortality rates can be significantly reduced if ACLF can be resolved.

1Moreau R et al, CANONIC Study Investigators of the EASL–CLIF Consortium. ACLF is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology. 2013 Jun.
2Hernaez R, et al. Prevalence and short-term mortality of acute-on-chronic liver failure: A national cohort study from the US. Journal of Hepatology Volume 70, Issue 4 p639-647 April 2019.
3Kamath PS. Acute on chronic liver failure. Clin Liver Dis (Hoboken). 2017 Apr 20;9(4):86-88

Our aim: to reverse ACLF 2-3 in intensive care and transform outcomes

By removing blood toxins and replacing dysfunctional albumin, we aim to shorten the time to ACLF resolution and significantly improve survival.

Extracorporeal liver support device YAQ002


• Removes damaged albumin
• Replaces functional albumin
• Removes endotoxins
• Shortens the time to ACLF resolution*
• Aims to reduce 28-day mortality

* Proof of concept in phase 2a randomized controlled trial in 30 patients

Our pipeline

The UK registrational study is being run by the ALIVER Consortium with funding from the National Institute for Health and Care Research (NIHR) under their Invention for Innovation program. Leading the study are co-principal investigators Prof. Banwari Agarwal and Dr Rohit Saha at the Royal Free Hospital, together with Yaqrit Founder and CMO Prof. Jalan at University College London (UCL), Dr Sameer Patel at Kings College Hospital London, and Dr Mansoor Bangash at the Queen Elizabeth Hospital, Birmingham.

Our Leadership

Cytox currently benefits from key members of Yaqrit’s leadership team. In time permanent Cytox appointments will be made.
Prof. Rajiv Jalan, Ph.D. Prof. Rajiv Jalan, Ph.D. Chair, Founder, CMO/CSO

Professor of Hepatology and Head of the Liver Failure Group at UCL. Key opinion leader in advanced liver disease and ACLF, extensively published

Troels Jordansen Troels Jordansen Chief Executive Officer

Over 35 years in commercial and senior leadership roles in life-sciences with an established track record in funding and growing companies

Karen Church, Ph.D. Karen Church, Ph.D. Head of RA, QA, and Clinical Operations

Clinical and regulatory specialist. Overseen submission of 27 NDAs/MMAs/PMAs and hundreds of INDs/CTAs

Carrie Morgan Carrie Morgan SVP Clinical Operations

More than 35 years clinical operations experience including overseeing phase 2/3 studies and securing funding in research innovation

Mary-Ann Chang, CFA Mary-Ann Chang, CFA SVP Communications and Strategy

Strategic communicator with more than 25 years of experience in the life-science industry, covering IR, communication and healthcare investment

Jan Bart Hak, Ph.D. Jan Bart Hak, Ph.D. Clinical, Regulatory and Quality Management Director Medtech, Regulatory Sciences, EU, ProPharma

Over 20 years of Clinical Research experience and 10 years of Regulatory and Quality Management Services for medical devices